Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $12.12, but opened at $12.89. Maze Therapeutics shares last traded at $13.35, with a volume of 12,580 shares.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on MAZE shares. Wedbush initiated coverage on shares of Maze Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $17.00 target price on the stock. Guggenheim reaffirmed a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $23.50.

Maze Therapeutics Trading Down 3.8%

The stock's 50 day moving average is $11.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund bought a new stake in Maze Therapeutics in the first quarter valued at approximately $25,000. Corebridge Financial Inc. bought a new stake in shares of Maze Therapeutics during the 1st quarter worth about $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Maze Therapeutics in the 1st quarter valued at about $57,000. Rhumbline Advisers bought a new position in Maze Therapeutics in the 1st quarter valued at about $80,000. Finally, Deutsche Bank AG acquired a new stake in Maze Therapeutics during the first quarter worth approximately $98,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.